Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone-secreting and non-functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans.
The aim of this study was to assess human intracranial tumours for their gene expression pattern of the vasoactive peptide adrenomedullin (AM), its receptor (AM-R) and leptin, which exerts multiple biological effects including proliferation and angiogenesis via the leptin receptor (OB-Rb). Gene activity of neuropeptide Y (NPY) was monitored additionally. We investigated whether there was a characteristic gene expression pattern of AM and leptin in different intracranial tumours, depending on their proliferation activity and biological behaviour. We investigated 35 non-functioning pituitary adenomas (including eight null cell, four silent plurihormonal, 23 silent gonadotroph adenomas), seven somatotropinomas, seven prolactinomas, eight meningiomas, five astrocytomas, two glioblastoma multiformes and unaffected temporal lobe (n = 8). Quantitative reverse transcriptase-polymerase chain reaction (TaqMan RT-PCR) was performed. AM mRNA was detectable in all tumour specimens. AM/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) ratio was significantly higher in somatotropinomas, as was AM/CD31 ratio in prolactinomas, compared with inactive adenomas (P < 0.05). AM-R mRNA was found in all tumour subgroups in small quantities but, in general, higher in tumours than in temporal lobe tissue, respectively. AM-R/CD31 ratio was significantly higher in prolactinomas than in inactive adenomas (P < 0.05). Leptin was detectable in very low quantities in each subgroup. OB-Rb gene expression was found in all tumour subgroups, OB-Rb/GAPDH ratio was highest for meningiomas (P < 0.0001, compared with temporal lobe). NPY mRNA was detectable in temporal lobe in higher quantities than in tumours (P < 0.0001), and almost undetectable in prolactinomas and astrocytomas. Our data demonstrate that AM and AM-R, NPY, as well as leptin and OB-Rb, are expressed in various intracranial tumours in humans but their particular function has to be elucidated further. At present, there is no evidence for a cross-talk on transcriptional level between the peptidergic vasodilative system AM and the putative angiogenic and proliferation affecting factor leptin.
Knerr
I
I
Departments of Paediatrics and Neurosurgery, University of Erlangen-Nuremberg, Germany.
Schuster
S
S
Nomikos
P
P
Buchfelder
M
M
Dötsch
J
J
Schoof
E
E
Fahlbusch
R
R
Rascher
W
W
D000236:Adenoma / Q000235:genetics* / Q000378:metabolism; D053607:Adrenomedullin; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics*; D002352:Carrier Proteins / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D020738:Leptin / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000235:genetics; D009479:Neuropeptides / Q000235:genetics*; D010455:Peptides / Q000235:genetics; D010911:Pituitary Neoplasms / Q000235:genetics* / Q000378:metabolism; D058265:Receptors, Adrenomedullin; D011956:Receptors, Cell Surface; D054411:Receptors, Leptin; D018000:Receptors, Peptide / Q000235:genetics
D002352:Carrier Proteins; D006728:Hormones; C515448:LEPR protein, human; D020738:Leptin; D009478:Neuropeptide Y; D009479:Neuropeptides; D010455:Peptides; D058265:Receptors, Adrenomedullin; D011956:Receptors, Cell Surface; D054411:Receptors, Leptin; D018000:Receptors, Peptide; D053607:Adrenomedullin